An artificial intelligence platform developed by AIIMS Delhi for cancer cure has been featured in the BRICS Health Journal, according to a statement by Dr Ashok Sharma, Professor and Head of the institute’s Neurobiochemistry department.
Sharma said he and his team had published an article highlighting the incidence of cancers. The statement does not specify the cancer types covered or provide details of the platform’s design, findings or use in patient care.
What is confirmed
The publication is linked to an AI platform developed by AIIMS Delhi for cancer cure. Sharma identified himself as the Professor and Head of the institute’s Neurobiochemistry department while discussing the article.
The material does not establish whether the platform is being used clinically, whether it has received any approval, or whether it has produced treatment outcomes. It also does not give details about the research methods, participating patients or the journal’s publication process.
Details yet to be clarified
The complete scope of the article is not yet available. The statement ends while referring to the incidence of cancers, leaving the specific findings and cancer categories unclear.
Information about the platform’s intended users, availability, treatment workflow and next development stage is also not available.
Conclusion
The confirmed development is the publication in the BRICS Health Journal of an AIIMS Delhi team article connected with an artificial intelligence platform for cancer cure. The platform’s functions and research findings still require clarification.
Frequently Asked Questions
Q. What has been published in the BRICS Health Journal?
An article by an AIIMS Delhi team connected with an artificial intelligence platform for cancer cure has been published.
Q. Who discussed the publication?
Dr Ashok Sharma, Professor and Head of the Neurobiochemistry department at AIIMS Delhi, discussed it.
Q. What does the article highlight?
Sharma said the article highlights the incidence of cancers.
Q. Is the AI platform available for patients?
Its availability for patients is not yet available.
Q. Has the platform’s clinical effectiveness been established?
The available details do not establish its clinical effectiveness.
Q. Which cancers are covered by the article?
The specific cancer types covered are not yet available.
Q. What does the platform do?
The platform is described as being developed for cancer cure, but its specific functions are not yet available.
